LISATA THERAPEUTICS, INC.
LSTALisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
Drugs in Pipeline
8
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
certepetide Phase 2 Results Expected
Primary completion for certepetide trial (NCT05712356) in Cholangiocarcinoma
SourceAuto-CD34+ cells
Chronic Myocardial Ischemia
therapeutic autologous dendritic cells
Melanoma (Skin)
CLBS16
Coronary Microvascular Dysfunction
NBS10
ST Segment Elevation Myocardial Infarction
CLBS14 (low-dose)
Myocardial Ischemia
CLBS03 Low Dose
Diabetes Mellitus
CLBS12
Critical Limb Ischemia
certepetide
Cholangiocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Auto-CD34+ cells | Phase 3 | Chronic Myocardial Ischemia | - | - |
therapeutic autologous dendritic cells | Phase 2 | Melanoma (Skin) | - | - |
CLBS16 | Phase 2 | Coronary Microvascular Dysfunction | - | - |
NBS10 | Phase 2 | ST Segment Elevation Myocardial Infarction | - | - |
CLBS14 (low-dose) | Phase 2 | Myocardial Ischemia | - | - |
CLBS03 Low Dose | Phase 2 | Diabetes Mellitus | - | - |
CLBS12 | Phase 2 | Critical Limb Ischemia | - | - |
certepetide | Phase 2 | Cholangiocarcinoma | - | - |
Critical Limb Ischemia
1 drug in this indication
Melanoma (Skin)
1 drug in this indication
Coronary Microvascular Dysfunction
1 drug in this indication
Chronic Myocardial Ischemia
1 drug in this indication
ST Segment Elevation Myocardial Infarction
1 drug in this indication
Cholangiocarcinoma
1 drug in this indication
Myocardial Ischemia
1 drug in this indication
Diabetes Mellitus
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)